abs19.txt	cell-free	dna	(cfdna)	is	a	liquid	biopsy	marker	that	can	carry	signatures	(i	e		mutations)	associated	with	certain	pathological	conditions	therefore	theextraction	of	cfdna	from	variety	clinical	samples	be	an	effective	andminimally	invasive	source	markers	for	disease	detection	and	subsequentmanagement	in	the	oncological	diseases	circulating	tumor	(ctdna)	cfdnasub-class	clinically	actionable	mutations	coupled	nextgeneration	sequencing	or	other	mutation	methods	provide	venue	foreffective	vitro	diagnostics	however	mutational	analyses	require	highquality	inputs	this	necessitates	extraction	platforms	high	recoveryover	entire	ctdna	size	range	(50	→	150	bp)	minimal	interferences	co-extraction	genomic	dna)	reproducibility	simple	workflow	herein	we	present	novel	microfluidic	solid-phase	device	(μspe)consisting	plastic	chip	activated	uv/o3	to	generatesurface-confined	carboxylic	acid	functionalities	μspe	μspeuses	immobilization	buffer	(ib)	consisting	polyethylene	glycol	saltsthat	induce	condensation	onto	surface	consists	array	micropillars	increase	bed	load(scalable	loads	>700	ng	cfdna)	produced	at	low-cost	usingreplication-based	techniques	fabricated	singlemolding	step	negating	need	adding	additional	supports	thedevice	simplifying	production	keeping	assay	cost	low	μspeallowed	recoveries	>90%	model	fragments	across	sizes(100-700	even	ability	extract	efficiently	short	fragments(50	bp	>70%)	addition	composition	ib	allowed	reducing	theinterference	co-extracted	demonstrated	utility	ofthe	by	quantifying	levels	healthy	donors	patients	withnon-small-cell	lung	colorectal	cancers	extracted	plasmasamples	was	also	subjected	ligase	reaction	(ldr)	determiningthe	presence	kras	gene	non-small	cell	lungcancer
